The FDA’s REMS policy, designed to ensure drug safety, is instead harming individuals with treatment-resistant schizophrenia ...
The first study to definitively show a link between cannabis use and schizophrenia was conducted in 1987 and examined 45,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback